GLOBAL NEWS COVERAGE
VERTICAL DESIGNS ENTERS LAND OPTION AGREEMENT WITH RENDAVI DEVELOPMENTS LTD.
March 1, 2013 – Vancouver, B.C.
Vertical Designs Ltd. is entering into an agreement with Rendavi Developments Ltd. to purchase 6.5 acres in Squamish, B.C.
Rendavi Developments intends to use the site to build and showcase VDL’s vertical farming technology and its ability to mass produce what is claimed to be the cleanest, highest quality produce and herbs in world.
All of the boutique packaged produce will be sold under the Vertical Designs trademarked brand, Eco Spirit. Operations within the province of B.C. will be headed by inventor and CEO, Nick Brusatore, who has personally designed and developed some of the worlds most advanced automated farming technology.
“I am pleased and excited to be working with Rendavi Developments,” commented Brusatore. “As we continue to build facilities throughout North America, we aim for optimum quality and efficiency through the use of our automated software. Our process meets and exceeds food safety certification, while dramatically reducing the water usage demands of traditional farming practices.”
While both companies are excited about the potential of revolutionizing food quality, they are equally enthusiastic about sustainable land development and local job creation.
Abattis receives US and Taiwan trademark approvals for anti-viral brand Defenzall™
VANCOUVER, Jan. 16, 2013 /CNW/ – Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (OTC PINK: ATTBF) (CNSX: FLU), announces it has been granted Intl Class 5 Trademark for DefenZall™ in Taiwan and the USA.
Mr. Mike Withrow, Chief Executive Officer on behalf of the Company, stated, “We are pleased to extend the intellectual property of the company as we grow our brands. This mark will be used to brand our proprietary Anti-Viral Nutraceutical Platform of products which are; DefenZall Daily™, DefenZall Immune Support™ and DefenZall Serious Defense™ They will be launched through our Canadian distributor Hedley Enterprises, on the Internet and via our Distributor in Hong Kong.”
About Abattis Bioceuticals Corp.
Abattis Bioceuticals Corp. is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of producing, licensing and marketing proprietary ingredients and bio-similar compounds for use in Pharmaceuticals, Nutraceutical, Cosmetic and Animal Nutrition markets. The company owns the exclusive world wide rights to the Vertical Designs Advanced Automated Growing Technologies for these markets. The company also has a deep pipeline of proprietary products ready for sale in high growth areas of Functional Foods and Supplements business. For more information, visit the Company’s website at www.abattis.com.
Abattis signs Andrew Riseman, Ph.D. Associate Professor, Applied Biology and Plant Breeding
VANCOUVER, Jan. 14, 2013 /CNW/ – Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (OTC PINK: ATTBF) (CNSX: FLU), announces the engagement of Andrew Riseman Ph.D. effective January 11, 2013. Dr. Riseman will be assisting the Company in Applied Biology and Plant Sciences.
Mr. Mike Withrow, Chief Executive Officer on behalf of the Company, stated, “We are pleased to have Dr. Risemanjoin our Abattis team. His expertise in tissue and plant breeding sciences will be a tremendous asset to Abattis; we will apply his knowledge to produce proprietary intellectual property for the company. “
Andrew Riseman Ph.D., Associate Professor, Plant Biology and Plant Breeding at UBC stated, I am very excited about this opportunity to work with such a great company to advance botanical sciences in the Medical Marijuana and other medicinal plant breeding sciences, I see Abattis a company with the ability to engineer, grow and extract advanced Pharmaceutical Grade Compounds “PGC’s” that ensure traceability, consistency in dosing and safety with a target to produce the purest compounds from chosen cultivars.”
About Abattis Bioceuticals Corp.
Abattis Bioceuticals Corp. is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of producing, licensing and marketing proprietary ingredients and bio-similar compounds for use in Pharmaceuticals, Nutraceutical, Cosmetic and Animal Nutrition markets. The company also has a deep pipeline of proprietary products ready for sale in high growth areas of Functional Foods and Supplements business. For more information, visit the Company’s website at www.abattis.com.
Abattis Signs Georges Laraque Management Inc. as Media and Product Champion
VANCOUVER, BRITISH COLUMBIA–(Marketwire – Jan. 7, 2013) - Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CNSX:FLU)(PINKSHEETS:ATTBF) announces the engagement of Georges Laraque Management Inc. effective January 1, 2013. Georges Laraque Management Inc. will be assisting the Company in Marketing and Branding all of the Natural Health Products designed by Abattis . As partial consideration for Georges Laraque Management Inc. entering into this agreement and providing services thereunder, the Company agreed to issue 150,000 shares of the Company at a deemed price of $0.10/share. The shares will be subject to a 4 month hold period as required by applicable securities laws.
Mr. Mike Withrow, Chief Executive Officer on behalf of the Company, stated, “We are pleased to have Mr. Laraque join our Abattis team. His professionalism and dedication to his political beliefs as Deputy Leader of the Green Party of Canada and his work done in Haiti, and PETA spokesperson, along with being Vegan, he has demonstrated during his career not only does have the ability but passion and drive and will help Abattis and its brands to be recognized and respected in political arenas, Athletic Performance Markets, Vegan Nutrition, and Animal Wellness Markets.”
Mr. Georges Laraque, Retired NHL Star and current Deputy Leader of the Green Party of Canada and Spokes Person for PETA stated, “I am very excited about this opportunity to work with such a great company and be able to further my support in the Natural Health Products arena, I see Abattis as a well poised company with advanced Pharmaceutical Grade Vertical Farming, Packaging and Extraction technologies to ensure people safety with the purest compounds with complete traceability from A-Z and I look forward to helping this company grow.”
Abattis Amends License Agreement with Vertical Designs Ltd. and Acquires Exclusive, Worldwide Rights to Bio-Pharma Patent License
VANCOUVER, BRITISH COLUMBIA–(Marketwire – Dec. 27, 2012) - Abattis Bioceuticals Corp. (“Abattis”) (CNSX:FLU)(PINKSHEETS:ATTBF) is pleased to announce that the Company has entered into an amended license agreement (the “Amended License Agreement”) which amends the terms of the license agreement previously entered into between the Abattis and Vertical Designs Ltd. (“Vertical Designs”) (see news release of November 15, 2012 for more details).
Under the Amended License Agreement, Abattis has now been granted the exclusive, worldwide rights to a patent license, with the right to grant sublicenses, to use the Bio-Pharma technology for growing products at licensed facilities, which products may only be used as ingredients in the pharmaceutical, neutraceutical, cosmetic and wellness markets, for total consideration of $600,000 to be paid by way of the issuance of 6,000,000 common shares of Abattis ($250,000, or 2,500,000 common shares of Abattis, of which was previously paid to Vertical Designs on execution of the original agreement). As the license grant was expanded from a British Columbia only non-exclusive license to a worldwide exclusive license, the royalty provisions of the license agreement were amended to reflect that: (i) the royalty payable on net sales of all products sold by Abattis was increased from 3% to 4%; (ii) in consideration for the grant of Abattis’ right to grant sublicenses, Abattis will pay to Vertical Designs a sublicense royalty of 15% of any monies or other consideration that Abattis receives from any sublicense; and (iii) after two years, Abattis will be required to pay to Vertical Designs a minimum royalty payment of $25,000 per year and if the combined royalty payments paid from (i) and (ii) above do not equal $25,000 in any given year then Abattis will be permitted to top up such amount with a cash payment.
Under the terms of the Amended Agreement, the patent license will revert to Vertical Designs in certain circumstances, including: (i) if Abattis terminates the Amended Agreement; (ii) if Abattis materially breaches or defaults in the performance of the agreement and has not cured such default within 60 days, or in the case of failure to pay any amounts due, then within 30 days, after receiving written notice from Vertical Designs specifying the breach; (iii) if Abattis discontinues its business of producing ingredients for pharmaceutical, neutraceutical, cosmetic or wellness markets; (iv) if Abattis fails to pay the annual $25,000 minimum royalty payment for any year ending after the second anniversary of the Amended Agreement; or (v) if Abattis becomes insolvent, makes an assignment for the benefit of creditors or has a petition of bankruptcy filed by or against it, which petition is not vacated or otherwise removed within 90 days after the filing thereof.
In addition, under the Amended Agreement all obligations related to the purchase of equipment and the building of licensed facilities were deleted from the license agreement and, in lieu thereof, the parties entered into a Bill of Sale pursuant to which Abattis agreed to pay Vertical Designs $250,000 for the purchase and sale of six complete Vertical Designs operational units of six levels high, totaling thirty-six levels, with touch screen software to control all lights, sensors and irrigation air flow along with 5 tonnes of HVAC for room controls. The purchase price will be paid in instalments, the dates and amounts of which will be determined between the parties, with the first instalment payment being due on or before the earlier of five business days following Abattis completing an equity and/or debt financing of any amount whatsoever or the first business day in the seventh month following the date of the Bill of Sale.
“After signing the BC license agreement in November, we have seen the medical marijuana policies in Health Canada and under US laws change,” stated Mike Withrow, President and chief executive officer of Abattis. “It was a combination of this, together with opportunities in other foreign countries with other plant tissue and medicinal applications, that played a major factor in our decision to acquire the exclusive world-wide rights to the Vertical Designs’ technology for use in the prescribed areas. We have put all of the pieces in place and we are now pushing forward with the process of making application to the government to become a participant in the rapidly changing marijuana market, which in November 2012 was estimated to be $46 Billion in the United States alone, assuming cannabis was legalized nationally there (Medical Marijuana Business Daily, November 27, 2012: potential US Marijuana Market Estimated at $46 Billion by Anne Holland). We feel this exclusive, world-wide license is a great compliment to the asset base and IP we have acquired over the past 18 months and it is now time to start implementing our strategy.”
Nick Brusatore, President and chief executive officer of Vertical Designs and recently appointed director of Abattis, commented, “I am very happy to make this deal for the shareholders of Vertical Designs and Abattis, as this will allow me and my team to focus on the implementation of our new automated mechanical pollinating strawberry systems along with the construction of our BC operations for herbs, spinach and various lettuces.” We are also very excited that Abattis will now be poised to establish itself in the marijuana markets in North America as they open up, with the ability to mass produce and extract under the highest level of protocol scrutiny for the safety of the North American people and deliver a solution to the mass production of this plant tissue.”
Abattis also announces that it has granted 1,615,000 incentive stock options to certain of its directors, officers and consultants, with each option being exercisable into a common share of Abattis @ $0.10/share for a period of five years.
Vertical Designs Ltd. Signs LOI With Cromogen Biotechnology
VANCOUVER, Nov. 8, 2012 /CNW/ – Vertical Designs Ltd. of Vancouver, B.C. is moving rapidly into the biotech, pharmaceutical, and nutraceutical arenas. The company has recently signed a letter of intent with Cromogen Biotechnology, a licensed research and development firm with offices in Central and South America. The union will spark cooperative research toward the augmentation of phytocannabinoids, (also called “natural cannabinoids”) through environmental changes and breeding.
Cromogen CEO, Michael Brubeck reports,”Cromogen sees great opportunity in accelerating research into cannabis plant physiology with Vertical Designs. With Stage 3 clinical trials beginning in Q2 2013, this will give our company greater efficiency in manufacturing isolated non-psychoactive molecules for use in our combination drug therapy, targeted for chemotherapy-induced nausea.”
“Cromogen offers a wealth of experience in greenhouse-based technology. As this team merges into the vertical farming arena, we see tremendous potential for even further advancement,” says Vertical Designs CEO, Nick Brusatore. “This progressive alliance will serve our vision to revolutionize agricultural and pharmaceutical practices on a global level.”
Vertical Designs has plans to spin off a wholly owned subsidiary company that will hold exclusive master licensing and rights of advanced designs in the biotech, pharmaceutical, and nutraceutical arenas. The firm will be seeking a capital partner in the near future.
Vertical Designs Ltd. closes another license deal for
Atlantic Region of Canada
VANCOUVER, Nov. 7, 2012 /CNW/ – Vertical Designs Ltd. of Vancouver, B.C. has just signed an exclusive licensing agreement with a non disclosed private local group from New Brunswick for the entire Atlantic Region Of Canada to construct a fully automated, indoor vertical farming facility. Products will include a series of top quality, pesticide-free fruits and vegetables that can be grown and harvested year round without any threat of seasonal changes or extreme weather challenges.
Vertical Designs CEO, Nick Brusatore reports, “With deals moving forward in the provinces of Ontario, Alberta, and now the entire region of Atlantic Canada Vertical Designs Ltd has become a national leader in the vertical farming movement. We look forward to supporting our current licensees and contributing to this amazing new brand of specialized farming on a global level.”
Vertical Designs Ltd. closes another license deal for
Province of Alberta
VANCOUVER, Oct. 31, 2012 /CNW/ – Vertical Designs Ltd. of Vancouver, B.C. has just signed an exclusive licensing agreement with Advanced Vertical Farming for the Province of Alberta to construct a fully automated, indoor vertical farming facility. Products will include a series of top quality, pesticide-free fruits and vegetables that can be grown and harvested year round without any threat of seasonal changes or extreme weather challenges.
“Alberta is a province rich in innovation and prosperous business practices,” says Advanced Vertical FarmingCEO, Greg Dennison. “It’s exciting to imagine the quality produce we’ll be able to grow and sell despite what the weather is doing outside. We effectively eliminate all of the environmental risks of traditional farming.”
Vertical Designs CEO, Nick Brusatore reports, “With deals moving forward in the provinces of Ontario and now Alberta, Vertical Designs Ltd. has become a national leader in the vertical farming movement. We look forward to supporting our current licensees and contributing to this amazing new brand of specialized farming on a global level.”
Advanced Vertical Farming Ltd. is currently seeking funding and is interested in a capital partner. Interested parties can contact Greg Dennison, CEO, at firstname.lastname@example.org
About Vertical Designs Ltd.
Vertical Designs Ltd. is helmed by Nick Brusatore – an innovative eco-entrepreneur, natural capitalist, mechanical designer, and inventor. Brusatore has presented on the benefits of vertical farm production facilities and energy saving technologies upon the international stage, including Vancouver, Haiti, New York, and various colleges and universities. Vertical Designs Ltd. is headquartered in Vancouver, British Columbia.
Abattis Bioceuticals inks LoI to buy BioPharma licence from Vertical Design
|Vancouver, British Columbia
Monday, October 22, 2012, 15:00 Hrs [IST]
|Abattis Bioceuticals Corp. a speciality biotechnology company focused on developing, licensing and marketing a range of neutraceutical products, has signed a Letter of Intent (LoI) with Vertical Design Systems Ltd. (VDSL).The LoI commences the process of conducting a sixty day (60 day) due diligence time period and begins the creation of a definitive agreement to acquire the exclusive rights for the area of British Columbia to a BioPharma licence and the Vertical Design System equipment.Under the terms of the LoI, the parties will evaluate and select an optimal deal structure with the objective of formalizing a definitive acquisition agreement. The company continues to deliver on its plan to become a fully integrated bioceutical company that offers cutting edge products to the medicinal, nutraceutical and cosmetic industries.”We are very pleased to find this excellent solution in hope to make Abattis Bioceuticals a fully integrated bioceutical company. Abattis will be able to demonstrate traceability in its raw material by growing and processing medicinal and therapeutic botanics. We can then extract bio-actives from the botanics we identify and target. As a result, the company will be able to produce and sell its own proprietary and patented products. Stated Mike Withrow, president and CEO of Abattis, “this initiative further validates our commitment to grow Abattis and commercialize our unique product line.”The parties have agreed to close the transaction on or before January 15, 2013.This agreement with Vertical Designs LTD is in keeping with the plans of Abattis Bioceuticals vertical expansion in order to create a powerful specialty biotechnology wellness company that will be one to follow.Vertical Designs Ltd. is helmed by Nick Brusatore – an innovative eco-entrepreneur, natural capitalist, mechanical designer, and inventor.SOURCE:http://pharmabiz.com/NewsDetails.aspx?aid=71797&sid=2|
Vertical Designs Ltd. Strikes Deal for Province of Ontario
VANCOUVER, June 25, 2012 /CNW/ – Vertical Designs Ltd. of Vancouver, B.C. is a brand new company to emerge in the vertical farming arena. Driven by CEO, Nick Brusatore, the firm has just signed an exclusive licensing agreement for the Province of Ontario to construct a fully automated, indoor vertical farming facility. The private capital group backing the project has plans to construct additional facilities to meet the demands of North America’s largest retailers. Products will include a series of top quality, boutique packaged, pesticide-free vegetables that can be grown and harvested year round without any threat of seasonal changes or extreme weather challenges.
CEO, Nick Brusatore is a long time vertical farming expert who currently serves on the Science Advisory Board for BG Medical Technologies. He also serves as chair of BCIT’s Centre for Applied Research and Innovation Advisory Committee. “I am very happy to be able to build this project with our new automated design,” commented Nick Brusatore, CEO. “We’re excited to unveil a number of new features that include alternative energy LED lights and a revolutionary composting system.”
Vertical Designs Ltd. sets its sights to become the global leader in vertical farming, while joining forces with other predominant green technologies.
BG Medical Welcomes Vertical Farming Expert Nick Brusatore
to Scientific Advisory Board
BG Medical Technologies adds advisory team to guide acquisitions and health technology development
LOS ANGELES, June 11, 2012 /PRNewswire/ – BG Medical Technologies, Inc. (OTC:RIGH) announced today that a Scientific Advisory Board (SAB) has been established to guide progress for the company’s BG Vision and BG Health Services programs. The function of the SAB is to provide advice and guidance in developing new solutions for natural medicinal production, diagnostic device design, and telehealth naturopathy services. The initial focus of the SAB will be on technology acquisitions to facilitate Internet-based solutions for the 50 million uninsured patients in the USA, and patients looking to augment traditional health care packages with cost effective nature-based practices.
BG Medical Technologies is pleased to announce that technology expert and pioneer in the vertical farming industry, Nick Brusatore, has agreed to join the SAB.
Mr. Brusatore is the CEO of Vertical Designs, Ltd., a firm for designing vertical farming technologies related to food and natural medicine production. Nick is the designer of TerraSphere systems and several well-established technologies for cloning and plant tissue propagation. He is an innovative eco-entrepreneur, natural capitalist, mechanical designer, and inventor. Nick has presented on the benefits of vertical farm production facilities and energy saving technologies upon the international stage, including Vancouver, Haiti, New York, and various college universities. Mr. Brusatore also serves as the Chairman of the British Columbia Institute of Technology’s Centre for Applied Research and Innovation Advisory Committee.
“BGMT is creating a world-class think tank of leaders in green health technologies,” commented Angel Stanz, CEO. “Mr. Brusatore will lend his experience and thought leadership in selecting and improving the best available technologies for use in our naturopathy health care systems, natural medicine, and nutraceutical production.”
About BG Medical Technologies
BG Medical Technologies develops ancillary support services for natural health treatment, patients, and professionals, including its flagship research laboratory and website portal, BudGenius.com. BG Medical Technologies, Inc. currently trades under the symbol OTC:RIGH. Symbol and name change pending.
The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management’s expectations could be affected by, among other things, uncertainties relating to our success in completing acquisitions, financing our operations, entering into strategic partnerships, engaging management and other matters disclosed by us in our public filings from time to time. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
Chief Executive Officer